Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Medical Journal of Indonesia Jurnal Penyakit Dalam Indonesia Cermin Dunia Kedokteran
Suhardi, Kevin Fernando
Unknown Affiliation
Health Professions Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Vaksin Influenza sebagai Modalitas Pencegahan Kejadian Rawat Inap Akibat Penyakit Kardiovaskular Rusdi, Lusiani; Adnan, Nurhayati; Suhardi, Kevin Fernando
Jurnal Penyakit Dalam Indonesia Vol. 10, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Penatalaksanaan Awal Takikardia Supraventrikular Paroksismal dengan Depresi Segmen ST pada Pengaturan Perawatan Primer: Laporan Kasus Suhardi, Kevin Fernando; Franky Kurniawan; Lusiani
Cermin Dunia Kedokteran Vol 52 No 6 (2025): Kesehatan Jiwa
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v52i6.1327

Abstract

Introduction: Supraventricular tachycardia (SVT) is a common cardiac emergency that can be life-threatening. Symptoms may include palpitations, chest pain, and difficulty breathing. Case: A 50-year-old male with sudden palpitations since one hour ago, accompanied by chest pain and breathing difficulty. A 12-lead ECG revealed an SVT rhythm with ST-segment depression in leads II, III, aVF, and V2-V6. After initial interventions, which included carotid massage, Valsalva maneuver, and oral bisoprolol, the rhythm converted to sinus rhythm within an hour. ST-segment depression may occur during SVT, which warrants evaluation for ischemic etiology. Conclusion: The report focuses on the initial management of SVT in a primary care setting with constraints on equipment and referral facilities. It's important to note that changes in the ST segment in SVT do not always indicate myocardial infarction, and further examination is necessary to confirm the diagnosis.
Empagliflozin for liver and lipid profile in metabolic dysfunction-associated fatty liver disease: a meta-analysis Suhardi, Kevin Fernando; Sutadji, Jonathan Christianto; Putri, Agustina Rajendra; Tsamara, Ghina; Faratisha, Icha Farihah Deniyati; Viazelda, Aqsha Tiara; Soeslistijo, Soebagijo Adi
Medical Journal of Indonesia Online First
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.13181/mji.oa.257855

Abstract

BACKGROUND Metabolic dysfunction-associated fatty liver disease (MAFLD) is a common chronic liver condition often associated with obesity and diabetes. Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, is an antidiabetic medication that improves glycemic control, insulin resistance, and body weight. This study aimed to examine the efficacy of empagliflozin in adults with MAFLD. METHODS A comprehensive literature search was performed using the PubMed, ScienceDirect, Cochrane Library, Scopus, and Wiley Online Library databases. Randomized controlled trials assessing liver function, lipid profile, metabolic profile, and body composition were included. Weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated using random-effects models, and study quality was assessed using the Cochrane Risk of Bias Tool for Randomized Trials. RESULTS 6 RCTs with a total of 636 participants were analyzed. Empagliflozin significantly reduced alanine aminotransferase levels (WMD: –6.65 IU/l, 95% CI: –13.02 to –0.28; p = 0.04) and gamma-glutamyl transferase levels (WMD: −10.60 IU/l, 95% CI: −29.05 to −7.68; p<0.00001). A non-significant reduction in aspartate aminotransferase was observed (WMD: –4.69 IU/l, 95% CI: –9.89 to 0.51; p = 0.08). Empagliflozin significantly improved low-density lipoprotein cholesterol (p = 0.02) and total cholesterol (p = 0.05) levels but did not significantly affect triglycerides, high-density lipoprotein cholesterol, metabolic profiles, or body composition. CONCLUSIONS This meta-analysis highlights the beneficial effects of empagliflozin on liver function and indicates the need for further research on its metabolic effects and long-term outcomes in managing MAFLD.
Co-Authors Adnan, Nurhayati Faratisha, Icha Farihah Deniyati Franky Kurniawan Lusiani Lusiani Rusdi, Lusiani Putri, Agustina Rajendra Soeslistijo, Soebagijo Adi Sutadji, Jonathan Christianto Tsamara, Ghina Viazelda, Aqsha Tiara